SP323EFFECTS OF RVX-208, A FIRST IN CLASS EPIGENETIC BET INHIBITOR, ON KEY RENAL PARAMETERS IN SUBJECTS WITH A HISTORY OF CVD, AND CHRONIC KIDNEY DISEASE (CKD); A POST-HOC ANALYSIS OF PATIENTS FROM THE ASSERT, SUSTAIN AND ASSURE CLINICAL TRIALS
2015
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI